Outcome in 203 patients (PTS) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX): Retreatment with fludarabine (FLU).

被引：0
|
作者：
Thomas, D [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, FJ [1 ]
Lerner, S [1 ]
Keating, MJ [1 ]
机构：
[1] Univ Texas, Md Anderson Canc Ctr, Leukemia Sect, Houston, TX USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
419
引用
收藏
页码：102A / 103A
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Zhou, Keshu
    Xing, Hongyun
    Teng, Qingliang
    Li, Wuping
    Wang, Yafei
    Zhu, Feng
    Jin, Zhengming
    Zhiming, Li
    Ouyang, Guifang
    Xu, Fang
    Huang, Shihua
    Li, Jianyong
    BLOOD, 2024, 144 : 4628 - 4628
  • [42] Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia
    Castagna, L
    Sarina, B
    Santoro, A
    BLOOD, 2003, 102 (06) : 2309 - 2309
  • [43] Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
    Koenig, Kristin
    Dotson, Emily
    Sheredy, Shane
    Bhat, Seema A.
    Byrd, John C.
    Wiczer, Tracy
    Woyach, Jennifer
    Awan, Farrukh T.
    Rogers, Kerry A.
    BLOOD, 2019, 134
  • [44] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Clinical efficacy and safety of combined thalidomide and fludarabine therapy in B-cell chronic lymphocytic leukemia patients.
    Dmoszynska, Anna
    Giannopoulos, Krzysztof
    Kowal, Malgorzata
    Podhorecka, Monika
    Wlasiuk, Paulina
    Bojarska-Junak, Agnieszka
    Trzesniewska, Wioletta
    Rolinski, Jacek
    BLOOD, 2006, 108 (11) : 332B - 332B
  • [46] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
  • [47] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [48] Phase-II-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL).
    Schulz, H
    Klein, SK
    Rehwald, U
    Reiser, M
    Ibach, S
    Aulitzky, WE
    Hensel, M
    Herold, M
    Huhn, D
    Knauf, U
    Hallek, M
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 364A - 364A
  • [49] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
  • [50] T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
    Kiaii, S
    Mozaffari, F
    Lundin, J
    Rezvany, R
    Chudhury, A
    Mellstedt, H
    Osterborg, A
    BLOOD, 2004, 104 (11) : 689A - 689A
12345